In one paragraphArticle in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Jie LvKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.
Zailin YangChongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.ORCID https://orcid.org/0000-0001-8773-1022 Xiaoqian LiuDepartment of Hematology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China.
Yao LiuChongqing Key Laboratory for the Mechanism and Intervention of Cancer Metastasis, Department of Hematology-Oncology, Chongqing University Cancer Hospital, Chongqing, China.ORCID https://orcid.org/0000-0003-1782-7322 Weiping LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0002-0367-1411 Jun ZhuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0003-3479-2547 Ling WangDepartment of Hematology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
Yuqin SongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0001-5451-6481 Chen ZhangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Lymphoma, Peking University Cancer Hospital & Institute, Beijing, China.ORCID https://orcid.org/0000-0002-8113-3264 Funding
Beijing Natural Science Foundation L244025Beijing Natural Science Foundation L244063Beijing Research Ward Excellence Program BRWEP2024W032150205Beijing Research Ward Excellence Program BRWEP2024W032150206Beijing Research Ward Excellence Program BRWEP2024W032150207Beijing Research Ward Excellence Program BRWEP2024W032150208Beijing Research Ward Excellence Program BRWEP2024W032150213Beijing Xisike Clinical Oncology Research Foundation Y-Young 2023-0286Capital's Funds for Health Improvement and Research 2022-1-2152Capital's Funds for Health Improvement and Research 2024-1-2151National Natural Science Foundation of China 82270195Noncommunicable Chronic Diseases-National Science and Technology Major Project 2023ZD0500800
6 · The paper itselfAbstract
The influence of bone marrow (BM) involvement at diagnosis on hematopoietic stem cell (HSC) mobilization outcomes remains to be fully elucidated, particularly in the contemporary plerixafor era. To address this issue, this multicenter retrospective cohort study including four lymphoma treatment centers evaluated patients who underwent their first autologous HSC mobilization procedure between January 2017 and June 2023. Mobilization success was defined as achieving a minimum CD34+ cell yield ≥ 2.0 × 10
Indexed as
Bone MarrowHematopoietic Stem Cell MobilizationHematopoietic Stem Cell TransplantationLymphomaAdultAgedAntigens, CD34FemaleHematopoietic Stem CellsHumansMaleMiddle AgedRetrospective StudiesAntigens, CD34bone marrowhematopoietic stem cellslymphomamobilization
Identifiers
PMID42565354
PMCPMC13449178
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390